Dr Marina Pajic

Marina is the Group Leader of the Personalised Cancer Therapeutics division at the Garvan Institute. She is also a Conjoint Senior Lecturer at St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney.
ROLE
  • SCITCRS 2019 Working Group

Background

Dr Marina Pajic completed her PhD in the laboratory of Professor Michelle Haber at the Children's Cancer Institute (CCI), University of New South Wales, where she investigated chemoresistance mechanisms in childhood cancers. On completion of her PhD, Marina joined Professor Piet Borst's group at the Netherlands Cancer Institute, where she established physiologically-relevant mouse models to study mechanisms of chemoresistance in breast cancer.

In 2010, Marina returned to Australia and joined the Pancreatic Cancer Research Team and the Australian Pancreatic Cancer Genome Initiative (APGI) at the Garvan Institute. Since 2013, Marina has lead the Personalised Therapeutics Group and has established a unique personalised medicine project for pancreatic cancer.

She has been awarded three fellowships from Cancer Institute NSW and a Philip Hemstritch Fellowship in pancreatic cancer. She is actively involved in training and mentoring young scientists, with all students currently supported by Sydney Catalyst, NHMRC and UNSW scholarships. In 2017 Marina was awarded the NSW Premier's Award for Outstanding Cancer Research Fellow and was recently awarded the Lorne Genome Young Investigator Award.

 

Research Interests

  • Prioritise and validate novel targets and therapeutic regimens in early development for the treatment of pancreatic cancer.
  • Expand the portfolio and clinical relevance of preclinical models of pancreatic cancer to serve as a platform for evaluating and prioritising novel therapeutic strategies.
  • Improve our understanding about the molecular evolution of tumours following therapy and the molecular mechanisms underpinning de novo and acquired resistance in pancreatic cancer.